Physician profile
Rachit Kumar
NPI 1316258148
$12,391.41
in general payments reported to CMS, 2019-2025
60 companies · $8,630 in 2025
The $8,630 reported for 2025 was more than what 87% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $27.57 · 2021: $91.68 · 2022: $289 · 2023: $1,207 · 2024: $1,646 · 2025: $8,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,880 · Food and Beverage: $4,874 · Travel and Lodging: $631 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,880.00 |
| Food and Beverage | $4,873.76 |
| Travel and Lodging | $630.54 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $6,671.17 | 2019-2025 | Onivyde, Somatuline Depot |
| Astrazeneca Pharmaceuticals Lp | $549.23 | 2020-2025 | Lynparza, Tagrisso, Calquence |
| Pfizer INC. | $439.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $395.64 | 2019-2025 | |
| Astellas Pharma US INC | $289.48 | 2023-2025 | Vyloy, Xtandi, Padcev |
| Merck Sharp & Dohme LLC | $269.79 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $263.66 | 2019-2025 | Fruzaqla, Alunbrig |
| Amgen INC. | $204.97 | 2019-2025 | Imdelltra (Amg757), Xgeva, Vectibix |
| Genentech USA, INC. | $200.76 | 2019-2025 | Polivy, Tecentriq, Rozlytrek |
| E.R. Squibb & Sons, L.L.C. | $190.51 | 2019-2025 | Opdualag, Opdivo, Krazati |
| Eisai INC. | $165.72 | 2022-2025 | |
| Glaxosmithkline, LLC. | $159.72 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Janssen Biotech, INC. | $139.21 | 2019-2025 | Darzalex, Talvey |
| Abbvie INC. | $137.65 | 2023-2025 | |
| Genzyme Corporation | $135.00 | 2022-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $134.82 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Tersera Therapeutics LLC | $133.56 | 2023-2025 | Zoladex, Xermelo |
| Regeneron Healthcare Solutions, INC. | $124.80 | 2023-2025 | Libtayo |
| Emd Serono, INC. | $114.71 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.44 | 2019-2025 | |
| Servier Pharmaceuticals LLC | $106.68 | 2023-2025 | |
| Taiho Oncology, INC. | $96.38 | 2023-2025 | |
| Gilead Sciences, INC. | $83.94 | 2023-2025 | Trodelvy |
| Celgene Corporation | $83.58 | 2019-2024 | Pomalyst, Reblozyl |
| Daiichi Sankyo INC. | $59.25 | 2023-2025 | Vanflyta, Injectafer, Enhertu |
| Puma Biotechnology, INC. | $58.61 | 2020-2025 | |
| Lilly USA, LLC | $58.51 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Stemline Therapeutics INC. | $57.44 | 2023-2024 | Orserdu |
| Seagen INC. | $55.96 | 2023 | Adcetris, Tivdak |
| Deciphera Pharmaceuticals INC. | $55.21 | 2023-2025 | Qinlock, Romvimza |
| Jazz Pharmaceuticals INC. | $54.82 | 2024-2025 | |
| Pharmaessentia USA Corporation | $53.92 | 2024-2025 | Besremi |
| Karyopharm Therapeutics INC. | $49.70 | 2024 | Xpovio |
| Blue Earth Diagnostics | $48.92 | 2023-2024 | |
| Adc Therapeutics America, INC. | $48.80 | 2023-2025 | |
| Genmab U.S., INC. | $45.95 | 2023-2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $41.79 | 2023 | Imbruvica, Epkinly |
| Exelixis INC. | $41.20 | 2019 | |
| Morphosys, US INC. | $36.92 | 2021-2023 | Monjuvi |
| Rigel Pharmaceuticals, INC. | $34.30 | 2023-2024 | Tavalisse, Rezlidhia |
| Apellis Pharmaceuticals, INC. | $31.38 | 2024 | Empaveli |
| Beone Medicines USA, INC. | $27.99 | 2025 | Brukinsa |
| Kite Pharma, INC. | $25.02 | 2023 | Yescarta |
| Myovant Sciences INC. | $23.93 | 2022 | |
| Tg Therapeutics, INC. | $22.34 | 2022 | |
| Beigene USA, INC. | $21.81 | 2023 | Brukinsa |
| Clovis Oncology, INC. | $21.29 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.30 | 2025 | |
| Array Biopharma INC | $19.17 | 2024 | Mektovi, Lorbrena, Braftovi |
| Progenics Pharmaceuticals, INC. | $18.36 | 2022 | |
| Coherus Oncology, INC. | $18.07 | 2023 | |
| Recordati_rare_diseases_inc. | $17.79 | 2023 | Sylvant |
| Smith+Nephew, INC. | $17.26 | 2019 | |
| Novocure INC. | $17.19 | 2023 | |
| Agios Pharmaceuticals, INC. | $17.15 | 2024 | Pyrukynd |
| Fresenius Kabi USA, LLC | $16.20 | 2024 | Stimufend |
| Blueprint Medicines Corporation | $15.46 | 2023 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $15.30 | 2024 | |
| Ambu INC. | $14.32 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachit Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.